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The biomolecular era is rapidly becoming shaped around the supreme interest in targeted therapy for patients with
non–small cell lung cancer. Tissue analysis has become crucial in the definition of biomarkers and genomic signatures
able to predict the response to treatment or even survival. Lung screening programs and minimally invasive thoracic
surgery are jointly aimed at increasing the quantity and quality of specimens of non–small cell lung cancer caught at
the earliest stages with the attendant, significant, effect on patient survival. In addition, biomolecular researchers are
disclosing an ever-increasing cohort of patients with specific genetic mutations that make their cancer susceptible to
individualized treatment. When needed for immunohistochemical characterization, investigators are ready to request
‘‘research biopsies’’ to consolidate tissue availability for clinical trials, translational research, and in biobanks.
With unique and diverse tools in the surgical armamentarium, the thoracic surgeon plays a central role in this new
multidisciplinary professional environment, actively participating in creating the foundations of the biomolecular
era. (J Thorac Cardiovasc Surg 2012;144:S18-22)Withmore than 220,000 and 155,000 new cases of lung can-
cer and deaths from the disease estimated to occur in the
United States, one can assume that the role of the thoracic
surgeon in the molecular biology era of lung cancer man-
agement will be as central as it could have ever been.1
Among all cancers, lung cancer ranks second and first in
terms of the incidence and mortality in both genders. Re-
cently published data have demonstrated that, in the male
population, lung cancer contributes to the decrease in all
cancers in the United States by 38% owing to smoking ces-
sation policies implemented in the past.1 Nonetheless, the
issues of gender discrepancy and the development of lung
cancer in never smoker will polarize the attention of clini-
cians and researchers for the foreseeable future.2 In this set-
ting, collaborative institutional efforts are underway to
routinely search for prevalent genomic alterations in the
available tissue specimens. By the extensive resort to endo-
bronchial ultrasonography, endoscopic esophageal ultraso-
nography, and video-assisted thoracic surgery to integrate
mediastinoscopy and mediastinotomy, thoracic surgeons
are expected to provide a determinant contribution to pro-
vide tissue samples for biomolecular identification in the
context of multicenter biobanks.3,4 As an example, the
National Cancer Institute has endorsed the creation of the
Lung Mutation Consortium, a collaborative project
involving several academic institutions in the United
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construct trials investigating targeted therapy models.2
EFFECT OF BIOMOLECULAR ANALYSIS ON
PROVISION OF CARE AND EARLY DIAGNOSIS OF
LUNG CANCER
The heterogeneity of the provision of care and the lack of
standardization in the treatment of patients with lung cancer
have led to the implementation of collaborative models in
clinical practice based on a multidisciplinary approach.4,5
Earlier detection through screening programs designed for
high-risk populations combined with biomolecular identifi-
cation and staging appear today to be the main thrusts be-
hind the innovation in research and clinical management
of lung cancer.6 A recently published well-designed, large
(>53,000 participants randomized in 2 screening modality
arms, with>26,000 patients each) screening trial (National
Lung Screening Trial) comparing low-dose computed to-
mography screening and chest radiography yielded a 20%
relative reduction in the mortality from lung cancer in the
computed tomography group.6 Of the 1060 patients with
confirmed lung cancer, 57% had early-stage disease (stage
I and II according to the 6th edition of the American Joint
Committee on Cancer staging system). When compared
with that reported in the general US population, a reduction
in surgical mortality in the National Lung Screening Trial6
was observed (from 4% to 1%). Admittedly, the surgical
outcomes correlated with the success of the screening pro-
gram.6 Thus, the quality of the surgical care becomes 1 of
the factors affecting the quality of screening trials, as does
the potential for overdiagnosis (defined as the possibility
of detecting cancers that would have never become
symptomatic), radiation-induced health hazards, and cost-
effectiveness.6 With the design and implementation of
screening trial programs aimed at addressing these issues
to finally outline the selection criteria for screening high-
risk populations, the role of the thoracic surgeon should
be central in the diagnostic and therapeutic pathways ofery c September 2012
TABLE 1. Molecular abnormalities in NSCLC







EGFR mutation 10 30 Sensitivity to EGFR TKIs
EGFR increased 30 60 Conflicting data on sensitivityAbbreviations and Acronyms
ALK ¼ anaplastic lymphoma kinase
EGFR ¼ epidermal growth factor receptor
NSCLC ¼ non–small cell lung cancercopy number to EGFR TKIs and
monoclonal antibodies
MET amplification 5 20 Resistance to EGFR TKIs;
indicates worse prognosis
MET mutation 3 3 Might be involved in EGFR
resistance
EML4-ALK fusion 5 7 Sensitivity to ALK inhibitors
k-ras mutation 10 30 Associated with smoking,
indicates worse prognosis
HER2 mutation 3 10 Resistance to EGFR TKIs
PIK3CA
amplification
12 12 Might be involved in RGFR TKI
resistance
PIK3CA mutation 2 13 Might be involved in EGFR TKI
resistance and might predict
response to PI3K/AKT/mTOR
inhibitors
BRAF mutation 3 3 Associated with smoking
IGF-IR increased
copy number
27 27 Indicates better prognosis in
operable NSCLC
ALK, Anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; EML4,
echinoderm microtubule-associated protein-like 4; IGF-IR, insulin-like growth factor
1 receptor; MET, mesenchymal to epithelial transition; NSCLC, non–small cell lung
cancer; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit
a-isoform; TKIs, tyrosine kinase inhibitors.earlier stage lung cancer. The real question is not about the
use of our expertise today—rather, it is about for how long
this expertise will be needed.3 Answering this question
might entail a re-assessment of both the quantitative and
the qualitative aspects of the thoracic surgical profession.
MOLECULAR BIOLOGY FOR THORACIC
SURGEONS
It all started with the issue of ‘‘not otherwise specified’’
lung cancer and the quest to avoid this inconclusive defini-
tion to facilitate targeted treatment of patients with lung
cancer.7 We were familiar with the distinction between
small- and non–small cell lung cancer, and we learned
that a histotype-specific (squamous vs nonsquamous) com-
bination of chemotherapeutic agents could improve long-
term survival.7 More recently, along the line of translational
research profiles in breast and colon cancer,2 a set of bio-
markers has been identified that are used to stratify patients
with lung cancer into prognostic categories8 (Table 1). In
addition, some of these biomarkers might serve the purpose
of substratifying patients with lung cancer according to the
response to specific, currently available chemotherapeutic
agents.9 National cooperative groups focused on cancer
management have already integrated this information into
their current decision algorithms.9 From a clinical stand-
point, the expression patterns in tissue samples of mutations
of epidermal growth factor receptor (EGFR), k-ras, and,
more recently, translocations of echinoderm microtubule-
associated protein-like 4 and anaplastic lymphoma kinase
(ALK) gene are being added to routine histotype character-
ization of surgical specimens from patients selected accord-
ing to tumor histotype, gender, age, ethnic origin, and
smoking history.10 EGFR mutations have been detected in
up to 15% of white and 40% of Asian populations.2 In con-
trast, ALK translocations are observed in up to 5% of
patients with NSCLC.10 Recently, at least 10% of patients
with NSCLC have been found to have c-met (a proto-
oncogene encoding hepatocyte growth factor receptor char-
acterized by tyrosine kinase activity) mutations.10 The
clinical correspondence lies in the remarkable control rates
using targeted agents, including tyrosine kinase inhibitors,
such as erlotinib and gefitinib (60-80% in patients with
EGFRmutations2), and crizotinib, an ALK and c-met inhib-
itor (90% in patients with NSCLC with the translocation
detected by fluorescent in situ hybridization10) (Figure 1).The Journal of Thoracic and CaNoteworthy is the mutual exclusivity of the genetic alter-
ations, which appear extremely rarely, if at all, in the
same patient with lung cancer.10 What about the predomi-
nant proportion of patients with NSCLC who do not present
with such genetic mutations? Reportedly, the association of
cetuximab (an EGFR monoclonal antibody) and current
chemotherapeutic regimens in patients with intense immu-
nohistochemical staining for EGFR might yield an overall
survival advantage compared with chemotherapy alone.11
Recently, in line with the observations from the outcomes
of translational research of other primary cancer types, the
concept of lung carcinogenesis as a process induced in the
bronchial epithelium through a sequence of superimposed
genetic mutations (ie, EGFR, k-ras, p53, ALK) has been
described.2 From this stepwise, progressivemalignant trans-
formation, the present views on the distinction among lung
cancer histotypes are being revisited.2 These histotypes,
albeit all arising in the lung, are thought to be fundamentally
different at amolecular level.2 A practical implication of this
novel molecular interpretation has yielded the clinicopatho-
logic distinction of adenocarcinomas into lepidic and solid
growths, each entailing a different prognostic outlook.12,13
Moreover, in this biomolecular prognostic model, p16
gene inactivation, EGFR mutation, and k-ras mutation
occur early in carcinogenesis, and p53 mutation, lossrdiovascular Surgery c Volume 144, Number 3 S19
FIGURE 1. Genetic foundations of individualized therapy. AMG102, humanized monoclonal anti-HGF IgG; EML4-ALK, echinoderm microtubule-
associated protein-like 4/anaplastic lymphoma kinase; IGF-1R, insulin-like growth factor 1 receptor; IMC-AT2, cixutumumab (humanized recombinant
IgG1/l monoclonal antibody); MET, mesenchymal to epithelial transition; PTEN, phosphatase and tensin homolog; TSG1/2, tumor suppressor gene 1/2;
VEGF, vascular endothelial growth factor; VEGFR, VEGF receptor. Reprinted with permission from Janku and colleagues.15
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develop late and correlate with invasive adenocarcinoma
(Figure 2).12 In addition, genomic signatures are being stud-
ied to understand the biomolecular changes induced by to-
bacco smoking.2 In particular, polymorphism variants of
the nicotinic acetylcholine receptor a- (CHRNA5 and
CHRNA3) and b- (CHRNB4) genes and glutathione trans-
ferases (glutathione transferase-m, q, and p) seem to be re-
lated to the development of lung cancer owing to theFIGURE 2. Sequential superimposed genetic abnormalities leading to carcin
permission from Noguchi and colleagues.12
S20 The Journal of Thoracic and Cardiovascular Surgenhanced susceptibility to tobacco byproducts.2 Genomic
signatures are also being studied to understand the trends
of age and gender-specific outcomes in patients with
NSCLC.14 As an example, Mostertz and colleagues14 at-
tempted to create a prognosticmodel of disease-free survival
by correlating the expression of tumor biology through the
activation of oncogenic pathways (including, among others,
EGFR, b-catenin, Ras, Myc, Src, tumor necrosis factor,
chromosomal instability, epigenetic changes, stemness,ogenesis (adenocarcinoma). LOH, Loss of heterozygosity. Reprinted with
ery c September 2012
FIGURE 3. The role of the thoracic surgeon in the biomolecular era.
EBUS, Endobronchial ultrasonography; EEUS, endoscopic esophageal ul-
trasonography; VATS, video-assisted thoracic surgery.
Rocco Session I: Lung Cancer Diagnosis and Stagingand invasiveness) to the clinical data of 787 patients with
NSCLC. In addition to genetic abnormalities, a constant in-
terplay between different oncogenic pathways aimed at ac-
tivating downstream segments, irrespective of interfering
blockades, has been described.15 The EGFR-activated phos-
phatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit
a-isoform—the AKT-mTOR and the RAS/RAF/MEK path-
ways exemplify this concept.15
Also, the molecular processes involved with tumor dis-
semination to metastatic sites have been investigated to de-
fine the possible prognostic implications. Epithelial to
mesenchymal transition is an example of a multistep path-
way program with reciprocal interactions at a molecular
level aimed at inducing phenotype alteration and functional
diversification.16,17 Endowed with enhanced motility, an
altered cell-to-cell relationship, and suitable structural flex-
ibility, the cells with a mesenchymal phenotype are released
from the intracellular matrix to enter the bloodstream and
reach predisposed niches in distant sites.16,17 The niches
are characterized by favorable microenvironments in
which a mesenchymal to epithelial transition takes place
to restore the original epithelial phenotype. In this setting,
the sarcomatoid NSCLC histotype embodies the
phenotypic changes seen in the epithelial to mesenchymal
transition program.2,17
MOLECULAR BIOLOGYAND SAMPLE SIZES:
ISSUE OF MANDATORY RESEARCH BIOPSIES
Expert pathologists are advocating a primary role in the
individualization of treatment for patients with lung cancer
inasmuch as standard biomarkers can be identified on small
biopsies with similar accuracy as from surgical specimens.18
Reportedly, 1 mm2 of material obtained from the tumor can
be used for RNA extraction and eventually yield a molecular
diagnosis.19 However, to curb the enthusiasm toward micro-
dissection,19 recent views seem to support moving away
from fine needle aspiration biopsy as the method of obtain-
ing an adequate diagnosis for subsequent treatment.2
The paradigm shift is obvious andmight mandate innova-
tion in perceiving the surgeon’s role in the multidisciplinary
management of lung cancer. One aspect could be exempli-
fied by the request for the collaboration of thoracic surgeons
in trials focused on TKIs administered in a neoadjuvant set-
ting to patients with early-stage lung cancer.20 Furthermore,
the resort to surgical ‘‘research biopsies’’ will increasingly
be needed to obtain adequate tissue for biomolecular stud-
ies.21 Although ‘‘clinical’’ biopsies are aimed at altering
management and might, at the same time, provide material
for ongoing trials, research biopsies are obtained exclu-
sively for research purposes without certain clinical ef-
fect.21 Nonetheless, only 1 of 5 patients accept the risk
inherent to research biopsies.22 In this context, the ethical
hurdles are as obvious as the potential advantages.21
Thus, the concept of surgical research biopsies is destinedThe Journal of Thoracic and Cato raise intense controversies in the international thoracic
surgical community.22 Guidelines to regulate the extent
and modality for research biopsies are being imple-
mented.21,22 As an example, research biopsies should be
contemplated when a biomarker is needed to determine
patient eligibility for trial entry, to finalize targeted
therapy, to determine a primary endpoint of a study, or to
address an issue not solvable by the analysis of archived
material.22 Viable diagnostic alternatives are represented
by molecular imaging, the identification of biomarkers in
the peripheral blood, the molecular identification of circu-
lating tumor cells, and, the availability of assays that can
be derived from paraffin preparations in lieu of frozen sec-
tion analysis.2 In the future, another breakthrough in the
early diagnosis of lung cancer is likely to derive from epige-
netics (ie, the study of phenotypic changes induced by
mechanisms other than genetic mutations).2,23 Examples
of epigenetic alterations are DNA methylation and histone
deacetylation.2 The hypermethylated promoter of tumor
protein 16 can be found in the sputum of current smokers
3 years before the clinical diagnosis of lung cancer.2 Like-
wise, aberrant methylation of the gene locus can lead to the
downregulation of cadherin 13 (T cadherin), which results
in phenotypic changes and tumorigenic features similar to
the activation of the epithelial to mesenchymal transition
program (Figure 3).2,24CONCLUSIONS
In recent decades, thoracic surgeons developed an ex-
traordinary interest in minimally invasive surgery and in
not strictly technical but equally important issues such
as the quality of care and risk assessment. Today, biomo-
lecular models represent an intriguing research domain
characterized by a remarkable potential for clinical corre-
lates and innovation of the therapeutic strategies for pa-
tients with lung cancer. For the thoracic surgeon,
keeping abreast of the developments in molecular biology
in the field of thoracic oncology is rapidly becomingrdiovascular Surgery c Volume 144, Number 3 S21
Session I: Lung Cancer Diagnosis and Staging Roccoa professional imperative, rather than an additional educa-
tional opportunity.
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